-DOCSTART- -X- O
Ebola -X- _ O
virus -X- _ O
is -X- _ O
the -X- _ O
causative -X- _ O
agent -X- _ O
of -X- _ O
Ebola -X- _ O
virus -X- _ O
disease -X- _ O
in -X- _ O
humans. -X- _ O
The -X- _ O
lethality -X- _ O
of -X- _ O
Ebola -X- _ O
virus -X- _ O
infection -X- _ O
is -X- _ O
about -X- _ O
50 -X- _ O
% -X- _ O
, -X- _ O
supporting -X- _ O
the -X- _ O
urgent -X- _ O
need -X- _ O
to -X- _ O
develop -X- _ O
anti-Ebola -X- _ O
drugs. -X- _ O
Glycoprotein -X- _ O
( -X- _ O
GP -X- _ O
) -X- _ O
is -X- _ O
the -X- _ O
only -X- _ O
surface -X- _ O
protein -X- _ O
of -X- _ O
the -X- _ O
Ebola -X- _ O
virus -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
functionally -X- _ O
critical -X- _ O
for -X- _ O
the -X- _ O
virus -X- _ O
to -X- _ O
attach -X- _ O
and -X- _ O
enter -X- _ O
the -X- _ O
host -X- _ O
cells -X- _ O
, -X- _ O
and -X- _ O
is -X- _ O
a -X- _ O
promising -X- _ O
target -X- _ O
for -X- _ O
anti-Ebola -X- _ O
virus -X- _ O
drug -X- _ O
development. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
using -X- _ O
the -X- _ O
recombinant -X- _ B-Patient
HIV-1 -X- _ I-Patient
/ -X- _ I-Patient
Ebola -X- _ I-Patient
pseudovirus -X- _ I-Patient
platform -X- _ I-Patient
we -X- _ O
previously -X- _ O
established -X- _ O
, -X- _ O
we -X- _ O
evaluated -X- _ O
a -X- _ O
small -X- _ O
molecule -X- _ O
library -X- _ O
containing -X- _ O
various -X- _ B-Intervention
quinoline -X- _ I-Intervention
compounds -X- _ I-Intervention
for -X- _ I-Intervention
anti-Ebola -X- _ I-Intervention
virus -X- _ I-Intervention
entry -X- _ I-Intervention
inhibitors. -X- _ I-Intervention
Some -X- _ O
of -X- _ O
the -X- _ O
quinoline -X- _ O
compounds -X- _ O
specifically -X- _ O
inhibited -X- _ O
the -X- _ O
entry -X- _ O
of -X- _ O
the -X- _ O
Ebola -X- _ O
virus. -X- _ O
Among -X- _ O
them -X- _ O
, -X- _ O
compound -X- _ B-Outcome
SYL1712 -X- _ I-Outcome
was -X- _ O
the -X- _ O
most -X- _ O
potent -X- _ O
Ebola -X- _ O
virus -X- _ O
entry -X- _ O
inhibitor -X- _ O
with -X- _ O
an -X- _ O
IC -X- _ O
( -X- _ O
50 -X- _ O
) -X- _ O
of -X- _ O
~1 -X- _ O
μM. -X- _ O
The -X- _ O
binding -X- _ O
of -X- _ O
SYL1712 -X- _ O
to -X- _ O
the -X- _ O
vial -X- _ O
glycoprotein -X- _ O
was -X- _ O
computationally -X- _ O
modeled -X- _ O
and -X- _ O
was -X- _ O
predicted -X- _ O
to -X- _ O
interact -X- _ O
with -X- _ O
specific -X- _ O
residues -X- _ O
of -X- _ O
GP. -X- _ O
We -X- _ O
used -X- _ O
the -X- _ O
time -X- _ O
of -X- _ O
the -X- _ O
addition -X- _ O
assay -X- _ O
to -X- _ O
show -X- _ O
that -X- _ O
compound -X- _ B-Outcome
SYL1712 -X- _ I-Outcome
blocks -X- _ O
Ebola -X- _ O
GP-mediated -X- _ O
entry. -X- _ O
Finally -X- _ O
, -X- _ O
consistent -X- _ O
with -X- _ O
being -X- _ O
an -X- _ O
Ebola -X- _ O
virus -X- _ O
entry -X- _ O
inhibitor -X- _ O
, -X- _ O
compound -X- _ B-Outcome
SYL1712 -X- _ I-Outcome
inhibited -X- _ I-Outcome
infectious -X- _ I-Outcome
Ebola -X- _ I-Outcome
virus -X- _ I-Outcome
replication -X- _ I-Outcome
in -X- _ I-Outcome
tissue -X- _ I-Outcome
culture -X- _ I-Outcome
under -X- _ I-Outcome
biosafety -X- _ I-Outcome
level -X- _ I-Outcome
4 -X- _ I-Outcome
containment -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
IC -X- _ I-Outcome
( -X- _ I-Outcome
50 -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
2 -X- _ I-Outcome
μM. -X- _ I-Outcome
In -X- _ O
conclusion -X- _ O
, -X- _ O
we -X- _ O
identified -X- _ B-Outcome
several -X- _ I-Outcome
related -X- _ I-Outcome
molecules -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
diaryl-quinoline -X- _ I-Outcome
scaffold -X- _ I-Outcome
as -X- _ I-Outcome
potential -X- _ I-Outcome
anti-EBOV -X- _ I-Outcome
entry -X- _ I-Outcome
inhibitors -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
can -X- _ I-Outcome
be -X- _ I-Outcome
further -X- _ I-Outcome
optimized -X- _ I-Outcome
for -X- _ I-Outcome
anti-Ebola -X- _ I-Outcome
drug -X- _ I-Outcome
development -X- _ I-Outcome
. -X- _ O

